文献速递免疫规划

将干扰素α靶向树突状细胞增强CD8+ T细胞对靶向人CD40的癌症疫苗的应答

Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine.
PubMed 文献 · Vaccine · 2017-07-23

研究比较了重组蛋白CD40靶向树突状细胞疫苗的交叉呈递,发现干扰素α刺激人血源树突状细胞是CD40靶向癌症疫苗诱导抗原特异性IFNγ CD8+ T细胞应答所必需。将干扰素α作为佐剂靶向树突状细胞可提高其诱导CD8+ T细胞抗原特异性产生IFNγ的能力,由此提出树突状细胞佐剂靶向概念。

要点

  • CD40是人树突状细胞抗原交叉呈递的有效受体靶点。
  • 干扰素α刺激人血源树突状细胞是CD40靶向疫苗诱导CD8+ T细胞应答所必需。
  • 将干扰素α靶向树突状细胞可增强疫苗诱导CD8+ T细胞产生IFNγ的能力。

核心结论

  • 将干扰素α作为佐剂靶向树突状细胞可增强CD40靶向癌症疫苗诱导CD8+ T细胞抗原特异性产生IFNγ的能力,由此提出树突状细胞佐剂靶向的概念。

研究设计与样本

  • 原文未报告研究设计与样本。

主要发现

  • 与体外来源的单核细胞树突状细胞相反,干扰素α刺激人血源树突状细胞是CD40靶向癌症疫苗诱导抗原特异性IFNγ CD8+ T细胞应答所必需。
  • 将干扰素α靶向树突状细胞增加了其诱导CD8+ T细胞抗原特异性产生IFNγ的能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8+ T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8+ T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8+ T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Graham JP, Authie P, Karolina Palucka A, et al. Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine. Vaccine. 2017. PMID: 28743486. doi:10.1016/j.vaccine.2017.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。